Pegcetacoplan in Geographic Atrophy: 24-Month Efficacy Results From the Phase 3 OAKS and DERBY Trials – Impact on Retinal Cells

Apellis Pharmaceuticals Inc. published this content on February 21, 2023, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on October 29, 2025 at 17:35 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]